Allan G. Kermode

No. 600 Tianhe Road
Guangzhou, 510630, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 152 publications

Multiple sclerosis outcomes after cancer diagnosis in people with recorded chemotherapy exposure: A real-world MSBase study.

Multiple sclerosis outcomes after cancer diagnosis in people with recorded chemotherapy exposure: A real-world MSBase study.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: August 03, 2026

Causal effects of multiple sclerosis therapies in left-truncated registry data.

Causal effects of multiple sclerosis therapies in left-truncated registry data.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: July 21, 2026

Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data.

Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: April 28, 2026

Corrigendum to "Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study" [Multiple Sclerosis and Related Disorders Vol 106; Feb 2026; Article Number 106885].

Corrigendum to "Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study" [Multiple Sclerosis and Related Disorders Vol 106; Feb 2026; Article Number 106885].

Journal: Multiple sclerosis and related disorders

Published: April 10, 2026

Meningoencephalitis and tumefactive demyelination are dominant factors for headaches in myelin oligodendrocyte glycoprotein antibody-associated disease.

Meningoencephalitis and tumefactive demyelination are dominant factors for headaches in myelin oligodendrocyte glycoprotein antibody-associated disease.

Journal: Multiple sclerosis and related disorders

Published: March 08, 2026

Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder.

Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder.

Journal: Neurology

Published: March 05, 2026

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: January 13, 2026

Immature CD10low blood neutrophils are enriched in people with multiple sclerosis.

Immature CD10low blood neutrophils are enriched in people with multiple sclerosis.

Journal: Frontiers in immunology

Published: January 07, 2026

Clinician-led, single-blind, randomised controlled trial evaluating the efficacy of a high-intensity resistance and impact training intervention for improving health-related quality of life in people with multiple sclerosis: protocol for STRONG-MS.

Clinician-led, single-blind, randomised controlled trial evaluating the efficacy of a high-intensity resistance and impact training intervention for improving health-related quality of life in people with multiple sclerosis: protocol for STRONG-MS.

Journal: BMJ open sport & exercise medicine

Published: December 30, 2025

Insights from a trial of narrowband UVB for early multiple sclerosis.

Insights from a trial of narrowband UVB for early multiple sclerosis.

Journal: Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology

Published: November 23, 2025

Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registry.

Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registry.

Journal: Therapeutic advances in neurological disorders

Published: November 09, 2025

Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry.

Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry.

Journal: Journal of neurology

Published: November 01, 2025

Showing 1-12 of 152

Last Updated: 09/26/2026